Narrative
Lung cancer is the commonest cause of cancer-related mortality worldwide. The University of Manchester (UoM) Lung Cancer Group has generated insights that underpin new standards of care in the treatment of advanced, metastatic small cell (SCLC) and non-small cell lung cancer (NSCLC), contributed to the results required for licensing of new drugs and secured approval for new treatment regimens now in routine clinical use internationally. Key contributions include an increase in survival of 23% in advanced NSCLC with the use of chemotherapy and doubling one-year survival from 13% to 27% in patients with incurable, extensive stage SCLC by the use of prophylactic cranial irradiation. The Group’s research has impacted on outcomes for thousands of patients worldwide.| Impact date | 2009 |
|---|---|
| Category of impact | Health impacts |
| Impact level | Benefit |
Documents & Links
Related content
-
Research output
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Research output: Contribution to journal › Article › peer-review
-
Prophylactic cranial irradiation in extensive small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
-
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
Research output: Contribution to journal › Article › peer-review
-
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
Research output: Contribution to journal › Article › peer-review
-
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
-
Impacts
-
New targeted therapies in Non-Small Cell Lung Cancer improve patient outcomes
Impact: Health and wellbeing, Economic